Covalent Inhibition in Drug Discovery

Citations Over TimeTop 1% of 2019 papers

Abstract

Although covalent inhibitors have been used as therapeutics for more than a century, there has been general resistance in the pharmaceutical industry against their further development due to safety concerns. This inclination has recently been reverted after the development of a wide variety of covalent inhibitors to address human health conditions along with the US Food and Drug Administration (FDA) approval of several covalent therapeutics for use in humans. Along with this exciting resurrection of an old drug discovery concept, this review surveys enzymes that can be targeted by covalent inhibitors for the treatment of human diseases. We focus on protein kinases, RAS proteins, and a few other enzymes that have been studied extensively as targets for covalent inhibition, with the aim to address challenges in designing effective covalent drugs and to provide suggestions in the area that have yet to be explored.

Related Papers

• → Covalent and non-covalent binding in vanadium–protein adducts(2020)23 cited
• → Covalent and non-covalent albumin binding of Au(i) bis-NHCsviapost-synthetic amide modification(2021)18 cited
• → Whole-animal cellular and molecular imaging to accelerate drug development(2002)97 cited
• → Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development(2021)16 cited
• → Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development(2010)